Your fact-checks will appear here
Neurocept is a commercial player in the over‑the‑counter nootropic or “brain‑support” supplement market, presented in product listings and an official site as an all‑natural capsule positioned as a co...
Neurocept is repeatedly presented in 2025 press and vendor pages as a New York City–based supplement brand; several press releases and consumer-facing sites list “New York City, NY” as the company loc...
Available public profiles and news coverage identify Neurocept primarily as a marketed brain‑health supplement sold through multiple “official” product sites; none of the provided sources name individ...
Available reporting about "Neurocept" is mixed and fragmented: some commercial press releases and multiple retail sites present Neurocept as a newly launched brain‑support supplement in November 2025 ...
Neurocept’s founding date cannot be conclusively determined from the supplied sources because multiple distinct legal entities with the name “Neurocept” appear in public records; evidence points to co...
Available sources show multiple consumer-facing "Neurocept" supplement websites and recent press releases positioning Neurocept as a new brain‑support supplement launched in 2025, but they do not name...
Neurocept appears in two distinct strands of the available record: a dissolved UK private limited company "NEUROCEPT LIMITED" incorporated 20 Nov 2015 and dissolved 25 Apr 2017 (Companies House), and ...
Neurocept is a marketed dietary-supplement brand with multiple commercial websites that sell a nootropic product; an official Companies House listing for NEUROCEPT LIMITED exists in the U.K., but the ...
The data sources supplied point to NEUROCEPT LIMITED’s Companies House profile and filing history but do not include the actual names of directors, officers or Persons with Significant Control (PSCs) ...
Neurocept is presented in multiple company-branded sites as a dietary nootropic supplement sold in the U.S., Canada and other markets; corporate records show at least one legally registered entity cal...
Available reporting does not identify a single, verifiable founder of “Neurocept” as a unified company; instead, multiple commercial websites present Neurocept as a dietary nootropic product and at le...
Available reporting does not identify a named founder of “Neurocept” or a clear corporate origin story; the brand appears primarily as a dietary-supplement product launched into the 2025 wellness mark...
Available public records and consumer-facing sites give mixed and limited information about “NeuroCept.” Companies named Neurocept appear in at least two different contexts: a UK-registered company "N...
Neurocept appears in two different corporate guises in available reporting: a UK-registered NEUROCEPT LIMITED (Companies House company number 09882135) with filings and a registered address in Birming...
Available reporting and public records in the provided search results do not show any clinical trials, FDA regulatory filings, or FDA correspondence that name a pharmaceutical company or founders spec...
Available public filings show a UK company named NEUROCEPT LIMITED was incorporated on 20 November 2015 (company number 09882135) and later dissolved on 25 April 2017 . Contemporary U.S. product pages...
Available reporting does not identify a major pharmaceutical company sponsoring clinical trials for a product called “Neurocept”; most found material presents Neurocept as a dietary supplement or cons...
Available reporting identifies multiple consumer-facing Neurocept supplement websites and promotional press releases that list U.S. locations (often New York City) and show ClickBank as the product re...
Neurocept appears in multiple product pages and press releases tied to a market push in November 2025; a Globe Newswire-backed article dated Nov. 7, 2025 describes Neurocept as a newly spotlighted cog...
Available sources do not provide a clear, contemporaneous statement naming an individual founder of "Neurocept LLC" in the United States; corporate records exist for a UK company called NEUROCEPT LIMI...